Comparative Pharmacology
Head-to-head clinical analysis: VEPESID versus VUMON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VEPESID versus VUMON.
VEPESID vs VUMON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Topoisomerase II inhibitor; induces DNA strand breaks by stabilizing the topoisomerase II-DNA complex, inhibiting DNA relegation and causing cell cycle arrest at G2 phase.
Teniposide is a semisynthetic podophyllotoxin derivative that inhibits topoisomerase II, causing DNA strand breaks and preventing relegation, thereby inhibiting DNA replication and cell division. It is cell cycle phase-specific, acting primarily in the S and G2 phases.
50-100 mg/m2 IV once daily on days 1-5, OR 100 mg/m2 IV once daily on days 1, 3, and 5, repeated every 3-4 weeks. Oral dose: 50-100 mg/m2 once daily for 14-21 days, repeated every 4 weeks.
130 mg/m2 IV over 1-2 hours daily for 3 consecutive days, repeated every 21 days.
None Documented
None Documented
Terminal elimination half-life: 4-11 hours (mean 8 hours). Clinically, no dose adjustment for mild renal impairment but caution in severe renal impairment (CrCl <10 mL/min) due to prolonged half-life.
Terminal elimination half-life is biphasic: initial phase half-life of 1-4 hours, terminal phase half-life of 15-25 hours in adults; clinical context: prolonged in hepatic impairment.
Renal (45-50% as unchanged drug), biliary/fecal (40-50% as metabolites and unchanged drug).
Primarily hepatobiliary excretion with fecal elimination (approximately 44% of dose); renal excretion accounts for about 6-10% as unchanged drug and metabolites.
Category C
Category C
Topoisomerase II Inhibitor
Topoisomerase II Inhibitor